Nuvation Bio Inc.
NUVB$522.74B
Mega CapNYSEPharmaceutical Preparations🇺🇸North AmericaNEW YORK
Drugs in Pipeline
4
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Oct 1, 2026
33wData is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply
Market Overview
Stock performance and market intelligence
Catalyst Timeline
1 upcoming, 1 past
🎯PDUFANext
FDA PDUFA Date NUV-868 (priority)
10/1/2026
For prostate cancer. NDA filing. Extracted from SEC filing: 8-K
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Drug Pipeline
Taletrectinib
Non Small Cell Lung Cancer
Crizotinib
Non Small Cell Lung Cancer
safusidenib
Glioma
NUV-1511
Advanced Solid Tumor
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
Taletrectinib | Phase 3 | Non Small Cell Lung Cancer | - |
Crizotinib | Phase 3 | Non Small Cell Lung Cancer | - |
safusidenib | Phase 3 | Glioma | - |
NUV-1511 | Phase 2 | Advanced Solid Tumor | - |
Regulatory & News
Approvals, filings, and latest developments
Regulatory Approvals
NUVB News